Summary of Study ST000939

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000648. The data can be accessed directly via it's Project DOI: 10.21228/M8X38B This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000939
Study TitlePredicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome using Plasma Metabolomics
Study TypeDiscovery Metabolomics
Study SummaryPaired citrate plasma samples were collected from 27 steroid-sensitive and 14 steroid-resistant nephrotic syndrome participants prior to beginning treatment and after an average of 7 weeks (range 3-19 wks) of treatment with a corticosteroid.
RTI International
LaboratoryNIH Eastern Regional Comprehensive Metabolomics Resource Core at UNC Chapel Hill (ERCMRC)
Last NameSumner
First NameSusan
Address3040 E. Cornwallis Road, Research Triangle Park, NC 27709, USA
Submit Date2018-03-01
Total Subjects86
Study CommentsFactor Description 1. Treatment Response R = Steroid Resistant; S = Steroid Sensitive; Steroid resistance was defined as failure to enter complete remission after 6-8 weeks of daily oral steroids; Steroid sensitive was defined as clinical remission after 6-8 weeks of daily oral steroids. 2. Draw Number Draw 1 sample, ‘Pre’, was collected at the time of disease presentation before even a single dose of glucocorticoids, and Draw 2 sample, ‘Post’, was collected after 6-10 weeks of Glucocorticoid therapy. 3. Age Age in years at the time of Draw 1, or 'Pre', sample collection Other sample data Weeks difference Time in weeks between draw 1, 'pre', and draw 2, 'post', treatment sample collection Gender M = male; F = female Race self-reported (Native American or Alaskan Native/Asian/Black or African American/Native Hawaiian or Other Pacific Islander/White/More than one race) Ethnicity self-reported (Hispanic or Latino/Not Hispanic or Latino/Unknown)
Raw Data AvailableYes
Analysis Type DetailNMR
Release Date2019-03-06
Release Version1
Susan Sumner Susan Sumner application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000648
Project DOI:doi: 10.21228/M8X38B
Project Title:Defining and Predicting Steroid-Resistance in Children with Nephrotic Syndrome by Metabolic Profiling
Project Type:Metabolomics
Project Summary:Nephrotic syndrome (NS) is a very common kidney disease in children. Glucocorticoids (GC) are the primary therapy, but are ineffective in ~20% of children and ~50% of adult cases. Patients with steroid resistant NS (SRNS) fail to enter remission after prolonged oral GC treatment, and are at high risk for GC-induced side effects and progression to end-stage kidney disease. This study aimed to discover markers of steroid resistance that could be potentially used to predict SRNS at presentation, and develop an improved mechanistic definition of pediatric SRNS. Plasma samples were collected from 30 steroid sensitive NS (SSNS) and 15 SRNS patients, and paired samples analyzed which were collected both at disease presentation, prior to any steroid therapy, and after ~7 weeks of daily GC treatment. Broad spectrum 1HNMR data were acquired, binned, and concentration fit. Multivariate analyses and hypothesis testing were used to determine the metabolites that best differentiated the four phenotypic groups. Treatment effects on metabolomics profiles were observed between paired Pre- and Post- treatment SSNS groups, and between Post SSNS and SRNS groups. Metabolites most perturbed by GC treatment included lipoproteins , adipate, pyruvate, alanine, creatine, glucose, tyrosine, valine, and glutamine. Logistic regression using a stepwise variable selection method was used on Pre- samples to model the odds at clinical presentation of SRNS. After controlling for age, the step-wise logistic regression model selected increased glutamine (OR= 1.01; 0.99-1.02 95% CI) as a marker of SRNS. A similar model with children age >3 only, indicated that children with reduced levels of malonate (OR=0.94; 0.89-1.00 95% CI) had an increased odds of SRNS . Thus, malonate concentration may be a potential plasma biomarker for identifying SRNS at initial clinical presentation.
Institute:The Ohio State University;Nationwide Children’s Hospital
Department:Department of Pediatrics and Center for Clinical and Translational Research
Last Name:Smoyer; Agrawal
First Name:William; Shipra
Address:700 Children's Drive, Columbus, OH 43205 and
Phone:(614) 722-4360
Funding Source:NIH Grants 1UMDK10086601, 1U24DK097193, and 7K01GM109320